Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of...
Reexamination Certificate
2006-12-07
2010-06-29
Ouspenski, Ilia (Department: 1644)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Reexamination Certificate
active
07745215
ABSTRACT:
The present invention provides methods and compositions for expanding Treg cells ex vivo or in vivo using one or more conjugates comprising a costimulatory moiety that stimulates at least one of three signals involved in Treg cell development and/or using dendritic cells pulsed with antigens and modified to display TGF-β, or hematopoetic stem cells or bone marrow cells modified to display TGF-β. The methods and compositions are useful, for example, in the treatment and prevention of autoimmune disease, including Type 1 diabetes and in preventing foreign graft rejection, as well as to establish mixed chimerism, induce tolerance to autoantigens, alloantigens or xenoantigens, beta cell regeneration, prevention of foreign graft rejection, and treatment of a genetically inherited hematopoietic disorder.
REFERENCES:
patent: 6232088 (2001-05-01), Franklin et al.
patent: 7238360 (2007-07-01), Shirwan
patent: 7598345 (2009-10-01), Shirwan et al.
patent: 2003/0219419 (2003-11-01), Shirwan
patent: 2006/0052295 (2006-03-01), Terman
patent: 1 736 482 (2006-12-01), None
patent: WO 00/67788 (2000-11-01), None
patent: WO 02/02751 (2002-01-01), None
patent: WO 2007/000675 (2007-01-01), None
Lynch D., Immunological Reviews, 2008, 222: 277-286.
Asai et al., “A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery”,Biomolecular Engineering, vol. 21, (1995), pp. 145-155.
Huang et al., “Improved Immunogenicity of a Self Tumor Antigen by Covalent Linkage to CD40 Ligand”,Int. J. Cancer, vol. 108, (2004), pp. 696-703.
Huang et al., “Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen”,Blood, vol. 96, No. 12, (Dec. 2000), pp. 3663-3670.
Rohrbach et al., “Targeted Delivery of the ErbB2/HER2 Tumor Antigen to Professional APCs Results in Effective Antitumor Immunity”,The Journal of Immunology, vol. 174, (2005), pp. 5481-5489.
International Search Report for International Application No. PCT/US2006/046662; mailed Nov. 13, 2007; (4 pgs.).
Office Action issued Apr. 21, 2008, in U.S. Appl. No. 11/635,066, 12 sheets.
Asai, T. et al.; “A human biotin acceptor domain allows site-specific conjugation o fan enzyme to an antibody-avidin fusion protein for targeted drug delivery”, Biomolecular Engineering, vol. 21, No. 6, pp. 145-155 (2005).
Huang, T-H, “Improved immunogenicity of a self-tumor antigen by covalent linkage to CD40 ligand”, Intl J. Cancer, vol. 108, pp. 696-703 (2004).
Huang, T-H, et al.; “Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen”, Blood, vol. 96, No. 12, pp. 3663-3670 (2000).
Rohrbach, F., et al., “Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity”, J. Immuno., vol. 174, No. 9, pp. 5481-5489 (2005).
Askenasy, Nadir et al., “Display of Fas Ligand Protein on Cardiac Vasculature as a Novel Means of Regulating Allograft Rejection”,Circulation, vol. 107, No. 11, pp. 1525-1531 (2003).
Briones, Javier et al., “Antitumor Immunity After Vaccination With B Lymphoma Cells Overexpressing a Triad of Costimulatory Molecules”,Journal of the National Cancer Institute, vol. 95, No. 7, pp. 548-555 (2003).
Kilinc, Mehmet O. et al., “Generation of a multimeric form of CD40L with potent immunostimulatory activity using streptavidin as a chaperon”,Experimental and Molecular Pathology, vol. 80, No. 3, pp. 252-261 (2006).
Hodge, James W. et al., “A Triad of Costimulatory Molecules Synergize to Amplify T-Cell Activation”,Cancer Research, vol. 59, pp. 5800-5807 (1999).
Singh, Narendra P. et al., “A Novel Approach to Cancer Immunotherapy: Tumor Cells Decorated with CD80 Generate Effective Antitumor Immunity”,Cancer Research, vol. 63, No. 14, pp. 4067-4073 (2003).
Singh, Narendra P. et al., “ProtEx™: A Novel Technology to Display Exogenous Proteins on the Cell Surface for Immunomodulation”,Ann. N.Y. Acad. Sci., vol. 1056, pp. 344-358 (2005).
Singh, Narendra P. et al., “Primary Tumor Cells Resected from Cancer Patients and Decorated with a Novel Form of CD80 Protein Serve as Effective Antigen-Presenting Cells for the Induction of Autologous T Cell Immune Responses Ex Vivo”,Human Gene Therapy, vol. 17, No. 3, pp. 334-346 (2006).
Yolcu, Esma S. et al., “Cell Membrane Modification for Rapid Display of Proteins as a novel Means of Immunomodulation: FasL-Decorated Cells Prevent Islet Graft Rejection”,Immunity, 17:795-808 (2002).
Moro, Monica et al., “Induction of Therapeutic T-Cell Immunity by tumor Targeting with Soluble Recombinant B7-Immunoglobulin Costimulatory Molecules”,Cancer Research, vol. 59, No. 11, pp. 2650-2656 (1999).
Symington, Frank W. et al., “Expression and Function of B7 on Human Epidermal Langerhans Cells”,Journal of Immunology, vol. 150, No. 4, pp. 1286-1295 (1993).
Kudo-Saito, Chie et al., “Intratumoral Vaccination and Diversified Subcutaneous/Intratumoral Vaccination with Recombinant Poxviruses Costimulatory Molecules”,Clincal Cancer Research, vol. 10, No. 3, pp. 1090-1099 (2004).
De Jong, Marg O. et al., “Biotinylation of interleukin-s (IL-2) for flow cytometric analysis of IL-2 receptor expression”,J. Immunol. Methods, 184:101-112 (1995).
Jordan, Robert A. et al., “Production of Genetically Engineered Biotinylated Interleukin-s and Its Applications in a Rapid Nonradioactive Assay for T-Cell Activation”,Clin.Diag. Lab. Immunol., vol. 10, No. 3, pp. 339-344 (2003).
U.S. Appl. No. 12/553,770, filed Sep. 3, 2009, Shirwan et al.
U.S. Appl. No. 12/499,488, filed Jul. 8, 2009, Shirwan et al.
Notice of Allowance issued on Jun. 5, 2009, by the Examiner in U.S. Appl. No. 11/635,066 (US 7,598,345).
Office Action issued on Feb. 24, 2009, by the Examiner in U.S. Appl. No. 11/635,066 (US 7,598,345).
International Search Report issued on Sep. 21, 2007 in application No. PCT/US2006/046663 (corresponding to US 7,598,345).
Rabu et al., “Production of Recombinant Human Trimeric CD137L (4-1 BBL): Cross Linking is Essential to its T Cell Co-Stimulation Activity,”The Journal of Biological Chemistry, vol. 280, No. 50, pp. 41472-41481 (Dec. 16, 2005).
Foley & Lardner LLP
Ouspenski Ilia
University of Louisville Research Foundation Inc.
LandOfFree
Methods and compositions for expanding T regulatory cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for expanding T regulatory cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for expanding T regulatory cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4242504